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To determine the genetic cause of the disease in the previously reported family with adult-onset
autosomal dominant distal myopathy (myopathy, distal, 3; MPD3).
Methods
Continued clinical evaluation including muscle MRI and muscle pathology. A linkage analysis
with single nucleotide polymorphism arrays and genome sequencing were used to identify the
genetic defect, which was verified by Sanger sequencing. RNA sequencing was used to in-
vestigate the transcriptional effects of the identified genetic defect.
Results
Small hand muscles (intrinsic, thenar, and hypothenar) were first involved with spread to the
lower legs and later proximal muscles. Dystrophic changes with rimmed vacuoles and cyto-
plasmic inclusions were observed in muscle biopsies at advanced stage. A single nucleotide
polymorphism array confirmed the previous microsatellite-based linkage to 8p22-q11 and
12q13-q22. Genome sequencing of three affected family members combined with structural
variant calling revealed a small heterozygous deletion of 160 base pairs spanning the second last
exon 10 of the heterogeneous nuclear ribonucleoprotein A1 (HNRNPA1) gene, which is in the
linked region on chromosome 12. Segregation of the mutation with the disease was confirmed
by Sanger sequencing. RNA sequencing showed that the mutant allele produces a shorter
mutant mRNA transcript compared with the wild-type allele. Immunofluorescence studies on
muscle biopsies revealed small p62 and larger TDP-43 inclusions.
Discussion
A small exon 10 deletion in the gene HNRNPA1 was identified as the cause of MPD3 in this
family. The new HNRNPA1-related phenotype, upper limb presenting distal myopathy, was
thus confirmed, and the family displays the complexities of gene identification.
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Distal myopathies are hereditary disorders with progressive
muscle weakness in the hands and/or ankles as the first
symptoms, and they consist of dozens of diseases.1-3 Finland
and Sweden are known for a high prevalence of some dominant
distal myopathies such as Welander distal myopathy4 and tibial
muscular dystrophy.5 In East Asia and Middle East, founder
mutations cause the higher prevalence of recessive GNE my-
opathy,3 whereas early-onset Laing distal myopathy occurs in
all populations with many different mutations, some of which
are de novo and independently reoccurring.6
We have previously described an adult-onset distal myopathy
(MPD3, OMIM: 610099) in a large Finnish family with a domi-
nantmode of inheritance7. The disease onset ranged from32 to 45
years and was generally earlier in the men of the family. Hand
weakness and stumbling on the feet were the first symptoms.
Muscle atrophy started in the small handmuscles and continued to
both anterior and posterior compartments of the lower legs, the
forearm muscles, and later to proximal muscles. Asymmetry of
muscle involvement was common. Muscle imaging showed fatty
degeneration of the affected muscles, and muscle biopsy revealed
frequent rimmed vacuoles and some cytoplasmic eosinophilic in-
clusions, besides general dystrophic changes with the loss of fibers
and increase of connective tissue. In 2004, a genome-wide scan of
microsatellites was performed on DNA samples from the family.
Two different chromosomal regions, 8p22-q11 and 12q13-q22,
showed linkage with equalmaximummultipoint logarithm of odds
(LOD) score 3.01, but Sanger sequencing revealed no rare variants
in the protein coding genes in the linked regions.8 Recently, we
renewed the analysis with a dense genome-wide genotyping array,
and the linkage was confirmed for both chromosomal regions.
Genome sequencingwas then performed on 3DNA samples from
affected members, and a small heterozygous deletion within the
linked region on chromosome 12 encompassing the second last
exon 10 of heterogeneous nuclear ribonucleoprotein A1
(HNRNPA1) (NM_031157.4, exon 9 in the shorter transcript
NM_002136.4) encoding the HNRNPA1 was identified. The
deletion was confirmed by Sanger sequencing and shown to be
expressed as a transcript lacking exon 10 on the RNA level. This
deletion segregated with the disease in the large family.
Methods
Patients
The patients provided written informed consent. The study,
approved by the ethics committee of the Helsinki University
Hospital, was performed in accordance with the Declaration of
Helsinki. Patients and healthy familymembers were available in
three consecutive generations (Figure 1). Clinical examination
and laboratory investigations were performed earlier and de-
scribed in detail in 6 patients.7,8 During this study, the material
was expanded with the assessment of 4 additional family
members, II-9, II-10, IV-10, and IV-11. Two of these 4 indi-
viduals, II-10 and IV-11, were affected. Patient IV-11 was di-
agnosed after clinical examination, showing early atrophy with
thin muscle bulks of thenar and hypothenar muscles. Previous
CT scans showed early minor lesions in lower leg muscles in
this male patient at the age of 28 years. His older brother IV-10
was unaffected. Patient II-10, a younger sister of the proband’s
mother, was not available for further clinical examinations, but
according to her medical records, she had clear walking diffi-
culties at the age of 50 and used a cane for walking.
Genome-wide Genotyping
A genome-wide single nucleotide polymorphism microarray
analysis (Illumina GSAMD-24 v2) with 730,000 markers was
performed on 13 available samples from three generations of
the family. The results were pooled. The arrays were run
according to the manufacturer’s instructions at the Institute
for Molecular Medicine Finland (FIMM, Helsinki, Finland)9
and analysed with the GenomeStudio Software using the
genomic build hg19. The data were filtered using PLINK
(version 1.9) (zzz.bwh.harvard.edu/plink/) before linkage
analysis and then filtered for minor allele frequency < 0.01.
The LOD score was calculated using single point analysis with
Merlin (version 1.1.2) (csg.sph.umich.edu/abecasis/merlin/
index.html). The internal Merlin error detection algorithm
was used for filtering and removing of erroneous genotypes. A
parametric linkage analysis was performed on the data for
complete penetrance model. Haplotypes were constructed,
allowing a minimum number of recombination events. The
SLINK program was used to estimate the maximum possible
LOD score for this pedigree.10
Genome Sequencing
DNA extracted from the blood of 3 affected family members
(II-7, IV-6, IV-11) was genome sequenced (GS), with an
average sequencing depth of 30 × (90 Gb) for two of the
samples (IV-6 and IV-11) and 50 × (150 Gb) for one of them
(II-7).11,12 The library construction and sequencing on a
DNBSEQ platform with paired end reads of 150 base pair
(bp) were performed at BGI, Tech Solutions, Hong Kong.
Standard bioinformatics and variant calling of the data were
performed by BGI.
CNV Detection Methods
The programs DELLY (v0.8.3)13 and LUMPY (v0.3.1)14
were both used with their default recommended settings. The
programs use information on paired end reads, split reads, and
Glossary
bp = base pair; CNV = copy number variant; DAFO = dynamic ankle foot orthosis; GS = genome sequencing; HNRNPA1 =
heterogeneous nuclear ribonucleoprotein A1; LOD = logarithm of odds; MPD3 = myopathy, distal, 3; MSP = multisystem
proteinopathy; PrLD = prion-like domain.
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read depth to delineate genomic rearrangements and copy
number variants (deletions and duplications), inversions and
translocations. Structural variant calling was performed sep-
arately for each of the three genome-sequenced family
members, and the results were evaluated separately for each
program. An in-house version of the program cnvScan15 was
used for further filtering of the results for rare structural var-
iants against both internal and public (gnomAD v2.1)16 da-
tabases of unrelated control samples. The comparison was
performed with a strict requirement of <1% frequency and
different overlap degrees (1 bp overlap, and 50% and 90%
reciprocal overlap). Both DELLY and LUMPY enable the
examination of possible translocations between the linked
regions by analysis of hybrid sequences.
Sanger Sequencing
PCR was performed on genomic DNA of the available sam-
ples from the family to confirm the 160 bp deletion in the
HNRNPA1 gene (hg19: chr12:54677979-54678138). The
primers were designed using the Primer3 program (bio-
informatics.nl/cgi-bin/primer3plus/primer3plus.cgi).17 The
forward primer was: tgggacctctttaccacctcc and the reverse
primer was actatgttgcactgctcagct. PCR products obtained
from the proband were cloned, and several clones were Sanger
sequenced to map the breakpoints.
RNA Extraction and Sequencing
RNA was extracted from the tibialis anterior muscle biopsy of
patient III-5 with Qiagen RNeasy Plus Universal Mini Kit
(Qiagen, Hilden, Germany) according to the manufacturer’s
instructions. The strand-specific RNAseq library was prepared
using the NEBNext Ultra II Directional RNA Library Prep kit
(E7760) for Illumina (NEB, Beverly, MA) at the Oxford
Genomics Center, Wellcome Trust Institute, Oxford, United
Kingdom. Whole transcriptome sequencing (RNAseq) was
performed on HiSeq4000 (Illumina), generating 59 million
paired end reads with 75 bp read length. Trimming was
performed using fastq:s, and the trimmed sequences were
mapped with STAR 2.7.0d using STAR 2-pass method.18
Gene level read summarization and quantification was per-
formed by featureCounts, and fragment counts were con-
verted into TPM counts.19 RNAseq data were analyzed as
described before.20,21
Immunofluorescence
Snap-frozen muscle biopsies of patients III-6, IV-7, and IV-11
were used for the preparation of 8 μmsections for hematoxylin&
eosin staining and immunofluorescent analysis using the stan-
dard methodology. Primary antibodies used were monoclonal
mouse (mAb) anti-HNRNPA1 (Abcam ab5832), pAb anti-p62
(Sigma-Aldrich P0067), and mAb anti-TDP-43 (Sigma-Aldrich,
clone 2E2-D3). Alexa fluor-488 and -546 conjugated secondary
antirabbit and antimouse antibodies were used for detection, and
the nuclei were counterstained using Hoechst. The slides were
analyzed using the Zeiss Axio ImagerM2 system using a 20×NA
0.80 objective (Carl Zeiss AG) or with a Leica TCS SP8 confocal
microscope using a 63× NA 1.12 objective (Leica
Microsystems).
Western Blotting
For western blotting analysis, the muscle biopsy from IV to 11
was homogenized in the Laemmli sample buffer and heated at
95°C for 5 minutes. The soluble fraction after centrifugation
(13,000 × g, 10 minutes) was collected and used for SDS-PAGE
Figure 1 Pedigree Chart of the Family
The proband (III-3) is indicated with an arrow. Available DNA samples indicated with asterisk (*). All available samples were used in the single nucleotide
polymorphism array.
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using 4%–20% TGX gradient gels and Bio-Rad Mini-
PROTEAN system (Bio-Rad Laboratories, CA). After separa-
tion, the proteins were transferred onto PVDFmembranes using
the Bio-Rad TransBlot Turbo device. The membranes were
incubated with anti-HNRNPA1 (Abcam ab5832) antibody at 1:
10,000, diluted in 5% nonfat milk powder/TBST, overnight at
+8°C. After HRP-conjugated secondary antibody incubation,
ECL reaction (SuperSignal West Femto, Thermo Fisher Sci-
entific) and Bio-Rad ChemiDoc reader were used for detection
of bands. The gels were recovered after transfer and stained with
Coomassie, and the myosin heavy chain bands were used as
loading control.
Standard Protocol Approvals, Registrations,
and Patient Consents
Informed consent was collected from the participants, and the
local ethics committee approved this study.
Data Availability
Pseudonymized data not published in this article are available
in RD-connect, as genomic data and clinical HPOs, and will
also be shared upon request to any qualified investigator.
Results
Clinical Investigations
Follow-up studies on the patients 15–20 years after initial
examinations showed a relatively benign evolution of the
disease. Patient III-3 (Figure 1) was still living by her own at
the age of 76 years and walked short distance without a walker
using dynamic ankle foot orthoses (DAFOs). She had severe
atrophies of hand muscles, weakness in the fingers, making
writing and similar hand skills very difficult despite aids to
improve hand grip. Patient III-5 had a similar disease evolu-
tion and was still walking without aids at the age of 70 years
using DAFOs and could even rise from the squat without
hand help. He was single living at home and could drive his
car. Reduced fine finger movements and hand weakness im-
paired daily life activities despite wrist orthoses. No cardiac
abnormalities were noted. Patient III-6 died of unrelated
cause at the age of 66 years. His son IV–11 was re-evaluated at
age of 42 years and now presented a clear phenotype with foot
drop, atrophy of small hand muscles, and preserved proximal
muscle strength. MuscleMRI showed fatty replacement of the
anterior compartment muscles of the lower legs (Figure 2).
Genetic Studies
The genome-wide linkage analysis was performed on DNA of
13 members of the family, of which 8 were affected and the
rest were healthy family members (Figure 1). Two potentially
linked areas on chromosomes 8 (hg19 chr8:18745476-
41425848) and 12 (hg19 chr12:48808721-92048193) were
identified, confirming the two previously linked genomic
areas.8 The highest LOD scores were 2.6 for both linked areas
and comparable with the expected maximum LOD score
calculated for this pedigree data set by the SLINK program,
which gave maximum scores between 2.3 and 2.7 (Figure 3).
Both loci are large. The 22.6 Mb region on chromosome 8
includes 435 known or predicted genes, of which 141 are
protein coding. The chromosome 12 region is approximately
Figure 2Muscle MRI of Patient IV-11 Show Selective Fatty Replacement of Tibialis Anterior and Long Toe Extensor Muscles
and Mild Early Degenerative Change in the Lateral Part of the Right Soleus Muscle and Both Rectus Femoris
Muscles
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43.2 Mb long including 986 known or predicted genes, of
which 387 are protein coding.
None of the SNV or indel variants identified by GS in these
linked regions by standard bioinformatic analysis seemed
potentially interesting. No translocations between the regions
on chromosomes 8 and 12 were evident. After filtering for
structural variant detections in the three affected samples,
some structural variants shared by the affected were found in
the linked regions, but most of these had frequencies of
Figure 3 Genetic Analyses
(A) LOD results for the single nucleotide polymorphism array for chromosome 8 and 12. Highest LOD scores 2. (B) A drop in read depth indicates the deletion
surrounding HNRNPA1 exon 10 in genomic sequencing of III-5. (C) The exact breakpoint was mapped by Sanger sequencing of a cloned PCR product. (D)
Effects on RNA and protein levels as seen in Sashimi plots of RNA sequencing data from a control sample and patient III-5. (Compare with the exon diagram in
E.) The patient sample shows reduced read count for HNRNPA1 exon 10, splicing of exon 9 to exon 11, and increased splicing to the alternative exons in the far
end of the 3’-UTR. (E) A schematic view of the 3’end of the HNRNPA1 gene (wild-type and deleted alleles) and theoretical protein products of the observed
transcripts. Splicing of exon 9 to exon 11 is predicted to result in themajormutant protein p.Gly356Asnfs*4, where the C-terminal amino acids are replaced by
a short tail encoded by exon 11. The possible minor protein product would contain a longer C-terminal tail encoded by the alternative far-3’-UTR exons.
HNRNPA1 = heterogeneous nuclear ribonucleoprotein A1; LOD = logarithm of odds.
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0.15–0.5 in the gnomAD structural variant database and could
hence be excluded. However, a small heterozygous deletion
encompassed the second last exon of the HNRNPA1 gene
(exon 10 of the long A1b isoform NM_031157.4) (Figure 3).
The breakpoints were in the intronic regions surrounding the
exon. This variant was not present in the gnomAD database
Figure 4 Histopathology
(A–B) Hematoxylin and eosin staining of patients IV-7 and III-6 showed advanced myopathology with rimmed vacuoles (arrow) and eosinophilic protein
inclusions (white arrowheads). (C) Immunofluorescent staining showed predominantly nuclear localization of HNRNPA1(magenta in all images) in patient IV-
11 with minor myopathology. (D) In patient III-6 HNRNPA1 shows increased sarcoplasmic labeling in several highly atrophic fibers. (E) In patient IV-7, there is
moderate HNRNPA1 accumulation pathology in one fiber (arrow), together with but apart from prominent p62 (green) inclusions. (F) TDP-43 (green)
inclusions in patient III-6. Scale bars 100 μm. (G) Confocal microscopy shows nuclear localization of HNRNPA1 in healthy control muscle. Nuclear localization
was less prominent in patient IV-7 and with some myonuclei being negative (arrowheads). Sarcoplasmic accumulation of p62 (green) and moderate
accumulation of HNRNPA1 (small arrows) was observed. Scale bar 20 μm. HNRNPA1 = heterogeneous nuclear ribonucleoprotein A1
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with any of the overlap evaluations. Sanger sequencing
(Figure 3) of cloned PCR products mapped the 160 bp de-
letion at chr12:54677979–54678138 and confirmed the seg-
regation of the variant with the disease.
RNAseq was performed on RNA from a biopsy of patient III-
5. The RNAseq data were analyzed for the expression of
transcripts of the HNRNPA1 gene20-22 and identified the
expression of an abnormal transcript without exon 10 in
addition to the normal transcript (Figure 3). A transcript
skipping exon 10 of HNRNPA1 was not observed in any of
our internal polyA RNAseq samples (n = 95), confirming it
is a direct consequence of the observed deletion (Figure 3).
The observed splicing of exon 9 to exon 11 would result in
the predicted protein product p.Gly356Asnfs*4 (NP_
112420.1) partially encoded by exon 11. Some reported
HNRNPA1 transcripts skip much of the 3’-UTR and use two
alternative exons (exons 10–11 in the transcript NR_
135167.2). Our RNAseq results suggested increased in-
clusion of exons in the far 3’-UTR, with 24% of mutant
transcripts using the far 3’-UTR vs 5% for the wild-type
transcripts. The predicted protein sequences are shown in
Figure 3.
Immunofluorescence and Western Blotting
Muscle biopsies from patients III-6, IV-7, and IV-11 were
available for further analyses. The biopsies of III-6 (obtained at
age 48) and IV-7 (at age 37) showed severe myopathology
including a high number of very atrophic fibers, with increased
endomysial connective tissue and fatty degeneration (Figure 4).
Frequent rimmed vacuoles were present, together with some
eosinophilic protein inclusions, and immunofluorescent staining
showed several fibers with smaller p62 inclusions in rimmed
vacuolated fibers and a few larger TDP-43 positive protein ac-
cumulations (Figure 4). In a subset of p62-positive fibers, sep-
arate modest HNRNPA1 positivity was observed (Figure 4). In
addition, HNRNPA1 showed diffuse sarcoplasmic labeling in
several fibers.
Biopsy of IV-11, obtained at the age of 39, represented early-
stage pathology, with minor fiber size variation and internal
nuclei, and very few rimmed vacuoles. No focal accumulation
pathology was observed, but a few atrophic fibers showed
diffuse HNRNPA1 signal (not shown). In the immunofluo-
rescence analysis, HNRNPA1 showed the anticipated nuclear
localization in healthy control muscle. In biopsies from III-6
and IV-7, a proportion of myonuclei were devoid of
HNRNPA1 and TDP-43 (Figure 4).
In western blotting of patient IV-11 with early disease-stage
biopsy, the HNRNPA1 isoforms A1a and A1b both showed
approximately 50% reduced expression in the patient muscle
(Figure 5). Additional bands of higher molecular weight,
possibly representing HNRNPA1 oligomers, were observed,
showing similarly reduced intensity in the patient. The epi-
tope of the used HNRNPA1 antibody is just upstream of the
mutation; hence, the antibody should recognize both wild-
type and mutant protein isoforms.23 Muscle samples from
other patients were not available for western blotting.
Discussion
HNRNPs are evolutionarily conservedRNA-binding proteins that
assemble with nuclear and cytoplasmic RNA to form ribonu-
cleoproteins. They are associated with the processing of RNAs
intomaturemRNAs by splicing, activation of gene expression, and
modulation of protein translation.22,24 The chromosomal deletion
identified in our patients contains an exon encoding part of a
distinctive prion-like domain (PrLD), which is essential for the
assembly of ribonucleoprotein granules. At least 240 humanRNA-
binding proteins contain PrLDs, low-complexity domains with
similar composition to prions.25 HNRNPA1 variations have been
associated with congenital heart defects,26 multiple sclerosis,27
and different phenotypes of the multisystem proteinopathy
(MSP) spectrum including myopathy.28-30 Most mutations in the
PrLD have been reported to accelerate the polymerization of
HNRNPA1 and to interfere with stress granule dynamics.27,28,30,31
Abnormal stress granule dynamics leading to protein aggregation
underlies also other degenerative diseases, such as distal myopa-
thies caused by mutations in the PrLD of TIA1.4,32 Thus,
Figure 5 Western Blotting
Both heterogeneous nuclear ribonucleoprotein A1 protein isoforms A1a (34
kDa) and A1b (39 kDa) were decreased in the biopsy from patient IV-11,
compared with a pooled control sample. Myosin heavy chain (MyHC) is
shown as loading control.
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HNRNPA1 was a good candidate gene for causing the observed
phenotype.
No potentially interesting missense variants nor copy number
variants (CNVs) were detected in the linked region on
chromosome 8, and we assume that the linkage to chromo-
some 8 seems just by chance without having any impact on
the disease. The Finnish population represents a genetic
isolate with several lines of remote common ancestries in-
creasing the likelihood of shared haplotypes.33
The small 160 bp deletion spanning exon 10 of the
HNRNPA1 gene in our family escaped several genetic at-
tempts over the years. Generally, small CNVs (<1000 bp)
are challenging to detect from short-read sequencing data,
with the evaluation of only-read depth differences. There-
fore, the choice of structural variant analysis programs used
on the genomic sequencing data was essential for the initial
detection of this variant, and the RNAseq results showed
convincingly that the deletion results in a transcript skipping
exon 10. This aberrant transcript is predicted to result in the
mutant protein p.Gly356Asnfs*4 (corresponding to
p.Gly304Asnfs*4 in HNRNPA1a, NP_002127.1), where the
17 most C-terminal amino acids, encoded by the second last
exon, are replaced by three amino acids encoded by the last
exon, which normally is in the 3’-UTR (Figure 3). It is im-
possible to unequivocally predict the consequences at the
protein level because splicing of exon 9 to the far 3’-UTR is
another possible event, which apparently is increased in the
mutant transcript according to our RNAseq data. If trans-
lated, this would lead to a novel 55 amino acid tail with no
homology to any known proteins.
While this article was under review, Beijer et al.30 reported
several novel pathogenicHNRNPA1 variants. Among these, 2
de novo mutations—a splice site mutation seen in a motor
neuropathy patient and a 500-bp deletion in a myopathy
patient—lead to the same p.Gly356Asnfs*4 protein change as
seen in our family, adding strong support to the pathogenicity
of these variants. In the functional studies of Beijer et al.,30 the
mutant HNRNPA1a protein showed reduced phase separa-
tion and fibrillization propensity, and accelerated stress
granule clearance, suggesting a pathomechanism distinct from
most other PrLD mutations. Of note, their RNAseq data also
indicated increased inclusion of the far 3’-UTR exons in the
patient harboring the 500-bp deletion, potentially giving rise
to the long minor mutant protein.
The fate of the mutant protein product(s) in patient muscle is,
however, unclear. In an IF analysis of patient IV-11 muscle
biopsy displaying minor pathology, HNRNPA1 showed, as
expected, primarily nuclear localization and no sarcoplasmic
expression. WB of the same biopsy indicated approximately
50% reduced expression of both HNRNPA1 isoforms
(Figure 5). We did not detect any additional bands compat-
ible with the predicted major or the possible minor mutant
protein products. However, the major mutant proteins are
only 1.4 kDa smaller than the respective wild-type forms and
might not separate well in SDS-PAGE. The lower HNRNPA1
level in early-stage muscle could suggest reduced stability of
the mutant protein. The major predicted mutant protein has a
C-terminal alanine residue and could show increased turnover
because of this C-degron,34 although the normal expression
level of the mutant protein in transfection studies30 argues
against this possibility.
Muscle biopsies from the patients III-6 and IV-7 with more
advanced muscle pathology were not available for WB. As
reported in previous publications on this family,7,8 the biopsies
from these patients showed extensive rimmed vacuolation and
large cytoplasmic protein inclusions. TDP-43 and SQSTM1/
p62 showed clear accumulation pathology, similar to previously
described HNRNPA1-related myopathies.29,30 HNRNPA1
seemed upregulated in a proportion of atrophic fibers in the III-
6 and IV-7 biopsies showing advanced myopathology. How-
ever, no strong focal cytoplasmic accumulation, similar to bi-
opsies with point mutations affecting HNRNPA1 aa 314,28,29
was observed in these samples. This difference in this family
could be due to a more C-terminal mutation, and it is in line
with reduced fibrillization propensity and accelerated stress
granule clearance observed by Beijer et al.30
Although identification of HNRNPA1 as the gene underlying
MPD3 resolves the genetic background of this disease, the
relationship of HNRNPA1 variants and the associated clinical
outcomes remains enigmatic. Besides myopathy, the MPD3
patients of our Finnish family did not show any symptoms of
the MSP spectrum such as Paget disease of the bone, fronto-
temporal dementia, or ALS. Pure myopathy was also reported
in families with the p.Asp314Asn mutation,29 originally iden-
tified in patients with ALS.28 On the other hand, variants
resulting in the same p.Gly356Asnfs*4 change as in our family
were reported in both myopathy and motor neuropathy pa-
tients (families D and A in ref. 30 respectively). The effects of
p.Asp314Asn and p.Gly356Asnfs*4 on HNRNPA1 fibrilliza-
tion propensity are essentially opposite.28,30 There is hence no
obvious correlation between the primary molecular patho-
mechanism and the clinical phenotype, and this needs to be
clarified in further studies.
Altogether, HNRNPA1 is a gene to consider in all unsolved
distal myopathies especially in dominant families.
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